Introduction {#S0001}
============

Compared with other drug forms, medical tablets and capsules are more superior with regard to portability and are the most common dosage form in Japan. However, the large size of some medical tablets/capsules makes it difficult to ingest them, causing discomfort to patients and sometimes leading to a decline in medication adherence.[@CIT0001],[@CIT0002]

To solve this problem, the global pharmaceutical industry should have knowledge regarding the size of medical tablets and capsules that is appropriate for patients. Several studies have investigated the shapes and sizes of medical tablets and capsules.[@CIT0003]--[@CIT0013] For example, Oshima et al suggested that tablets with a diameter greater than 7 mm are hard to ingest for elderly people.[@CIT0007] Hashimoto concluded that diameter of 7 mm is the most appropriate for elderly people to ingest.[@CIT0010] However, these studies had the following limitations: (i) most were small clinical studies involving healthy volunteers and did not reflect the evaluation and tolerance of real patients, (ii) most only investigated the diameter of round tablets and did not consider the three-dimensional shape of tablets, and (iii) the studies only compared patient preferences using different tablet/capsule sizes and did not focus on the appropriate size range or threshold size and, therefore, did not reveal information useful for drug formulation design and development.

In Japan, medical representatives (MRs) of pharmaceutical companies conduct postmarketing surveillance (ie, the collection of pharmaceutical information from clinical fields). However, MRs are generally the employees of pharmaceutical companies and are responsible for promoting their companies' products; therefore, this system of data collection has some limitations regarding its effectiveness: (i) MRs cannot collect information about other companies' products and (ii) MRs need to focus on communicating with doctors and thus get few opportunities to visit community pharmacies (especially in countryside) to assess pharmacists' opinions.[@CIT0014]

Conversely, in Japanese medical logistics, medical wholesalers act as brokers between pharmaceutical companies and medical institutions for an effective and stable supply of medicines. These medical wholesalers stock medicines from pharmaceutical companies, and some of their employees \[so-called marketing specialists (MSs)\] deliver ordered medicines to medical institutions on a daily basis. MSs deal in medicines from different pharmaceutical companies and frequently visit medical institutions; therefore, they can overcome the limitations of the current system for postmarketing information collection.

In November 2014, Toho Pharmaceutical Co., Ltd., Tokyo, Japan (one of the big4 medical wholesalers in Japan) developed a postmarketing surveillance system called "Postmarketing Event Monitoring Marketing Specialists" (PEM-MS). Since its inception, the PEM-MS system has been collecting and storing approximately 400 reports every week. Most of these reports include problems regarding medical tablets and capsules or their packaging.[@CIT0015] Some medical wholesalers have made similar postmarketing surveillance efforts;[@CIT0016],[@CIT0017] however, none of their efforts managed to generalize the collected information and to obtain useful knowledge from it.

The aims of this study are: (i) consider the three-dimensional threshold size of medical tablets and capsules from the collected clinical opinions and (ii) create pharmaceutical knowledge for drug formulation design and development from the information collected by MSs.

Patients and Methods {#S0002}
====================

Analyzed Data {#S0002-S2001}
-------------

Data for this study were retrospectively acquired from Toho Pharmaceutical, which stores opinions and requests related to medical tablets and capsules and their packages received by the company's MSs during their visits to medical institutions, such as hospitals and pharmacies. In all, 17,533 reports were collected from Tokyo region during November 2014--April 2016; these reports included the date of data collection, the profession of the medical worker, the name of the product, the nature of the product (such as formulation or package), and details of the medical worker's opinion or request. The data did not include any confidential or personal information, and ethical approval for this study by the Ethics Committee of the University of Tokyo was not required.

Of these 17,533 reports, 709 were included for analysis based on the following two inclusion criteria: the opinions or requests stating that (i) the medical tablet/capsule was too large and (ii) the medical tablet/capsule size annoyed patients, not medical workers. In addition, only the upper threshold size of medical tablets/capsules for patients was considered. There were only 89 reports stating that the medical tablet/capsule was too small for patients, and these reports were not considered owing to insufficient data.

Indices of Drug Size {#S0002-S2002}
--------------------

The authors attempted to make the elemental indices of tablet/capsule size in order to simplify their consideration during drug formulation design and development. The authors considered the following six indices of tablet/capsule size: (i) length, (ii) length + width, (iii) length + width + depth, (iv) length × width, (v) length × width × depth, and (vi) weight ([Figure 1](#F0001){ref-type="fig"}).Figure 1Indices of the size of medical tablets and capsules. The following six indices of medical tablet/capsule size were considered: (i) length, (ii) length + width, (iii) length + width + depth, (iv) length × width, (v) length × width × depth, and (vi) weight.

These indices were calculated using the data present in package inserts of reported medical tablets/capsules. For round medical tablets, both the length and width were considered as the diameter. For medical capsules, both the width and depth were considered as the diameter.

Using the aforementioned six indices, two analyses were performed: analysis of histograms of size distribution and geometric analysis using linear approximation.

Analysis of Histograms {#S0002-S2003}
----------------------

Histograms were generated using the aforementioned six indices. The *x* axes represented the scores of the indices and the y axes represented the number of reports. With regard to the threshold size of medical tablets/capsules, it was desirable for the histogram to show a drastic increase in the number of reports above a specific index score (*I*; [Figure 2](#F0002){ref-type="fig"}); this score identifying the drastic increase can be considered as the threshold size of medical tablets/capsules. Using the six histograms, we selected one index that the authors considered appropriate in order to estimate the threshold size of medical tablets/capsules and additionally performed an analysis.Figure 2Histogram of the index score (*x* axis) versus the number of reports (*y* axis) for determining the ideal index for determining the size of medical tablets and capsules.

Geometric Analysis with Linear Approximation {#S0002-S2004}
--------------------------------------------

The selected index was subjected to geometric analysis with linear approximation using Microsoft Excel 2016 ver. 1803 (Microsoft Corporation, WA, USA).

First, instead of a histogram, a continuous graph of the accumulated number of reports was plotted ([Figure 3](#F0003){ref-type="fig"}). The *x* axis represented the sum of the length, width, and depth of the medical tablets/capsules (0.1-mm increments, similar to the original data), and the *y* axis represented the accumulated number of reports. Because the bins of the histograms were constructed using 1-mm increments, there was a possibility of a distortion in histogram analysis. However, this problem was avoided using the continuous graph. In this graph, the bending point represented the point where the frequency of the reports drastically changed and, thus, was considered the threshold score and was calculated in the following manner ([Figure 4](#F0004){ref-type="fig"}): The analysis range was defined as 0--33 mm at *I*, where the frequency of reports droppedTo consider the geometric angle, the analysis range (approximately 700 × 33) was revised to a square areaAn arbitrary borderline was set to separate the entire area into two subareasIn each subarea, an approximation line of the graph was drawn and the coefficient was calculatedAn inverse trigonometric function was applied to the coefficient and linear approximation angles (*θ*~1~ and *θ*~2~) in the subareas were calculatedThe difference between the two linear approximation angles was determinedBy shifting the arbitrary borderline by 0.5-mm increments, the borderline that maximized the difference in linear approximation angles was determinedFigure 3Continuous graph of the accumulated number of reports. The *x* axis represents the sum of the length, width, and depth of the tablets/capsules (0.1-mm increments), whereas the *y* axis represents the accumulated number of reports.Figure 4Geometric analysis with linear approximation for the accumulated number of reports. The *x* axis represents the sum of the length, width, and depth of the medical tablets/capsules (0.1-mm increments), whereas the *y* axis represents the accumulated number of reports.

In this analysis, the linear approximation angle of one subarea nears to the linear approximation angle of the other subarea, and the difference declines if the bending point in the graph is included in the area. Maximum difference implies that the borderline equals the bending point. Therefore, the calculated borderline that maximizes the difference in linear approximation angles is the bending point in the graph and can be considered as the threshold size of medical tablets/capsules for patients.

Result {#S0003}
======

Analysis of Histograms {#S0003-S2001}
----------------------

[Figure 5](#F0005){ref-type="fig"} shows the histograms of the six indices. The *x* axes represent the calculated *I* of each medical tablet/capsule, and the *y* axes represent the number of reports in the *I* range. Three of the six indices were considered appropriate for medical tablet/capsule size: length (*I*~1~), length + width (*I*~2~), and length + width + depth (*I*~3~). As the other three indices, length x width (*I*~4~), length x width x depth (*I*~5~) and weight (*I*~6~), had wide and decentralized distribution, these were considered inappropriate to decide a threshold. After further observation, *I*~1~ was found to be inappropriate because it could not distinguish round medical tablets/capsules from oval medical tablets/capsules and showed two peaks. In addition, *I*~3~ was found to be better than *I*~2~ because *I*~3~ (the report increase ratio on the threshold was 14.7 times) had greater rise than *I*~2~ (4.6 times) and considered more dimensions. Consequently, the histograms showed that *I*~3~ was the most suitable index of medical tablet/capsule size.Figure 5Six histograms of six indices of the size of medical tablets and capsules. The *x* axis represents each index score. The width of each bin is 1 (histograms 1--3), 4 (histogram 4), or 20 (histograms 5 and 6). The *y* axis represents the number of reports.

The *I*~3~ histogram showed a drastic increase in negative reports on medical tablet/capsule size at a score of 21 mm. Therefore, *I*~3~ = 21 mm was considered the threshold size of medical tablets and capsules that patients feel are too large to ingest.

Moreover, a control histogram ([Figure 6](#F0006){ref-type="fig"}) of 200 products that were used most frequently in Japan in 2014--2015 was constructed and compared with the *I*~3~ histogram.[@CIT0018] The distributions of reported and frequently used medical tablets/capsules were different; the products reported with the size problem mainly exist between 21 and 32 mm, while most of the frequently used products were distributed between 15 and 22 mm, with the peak at 17 mm. Therefore, we concluded that there is no or ignorable effect of the distribution of medical tablets/capsules on the increase in the number of reports at *I*~3~ = 21 mm.Figure 6Histogram comparison between PEM-MS reports on problems and popular medical tablets/capsules in Japan. (Top): Distribution of problem reports in the PEM-MS system. (Bottom): Distribution of the 200 most popular medical tables/capsules in Japan in 2014--2015. The *x* axis represents the sum of the length, width, and depth of the medical tablets/capsules. The width of each bin is 1 mm. The *y* axis represents the number of reports or products. PEM-MS, postmarketing event monitoring marketing specialists.

Geometric Analysis with Linear Approximation {#S0003-S2002}
--------------------------------------------

To determine the bending point in the graph of *I*~3~ and the accumulated number of reports, the arbitrary borderline was shifted and the difference between linear approximation angles (*θ*~1~ and *θ*~2~) was determined. This difference between the two linear approximation angles was highest when the borderline was 21 mm ([Figure 7](#F0007){ref-type="fig"}).Figure 7Difference between linear approximation angles in the arbitrary borderline. The difference between the two linear approximation angles was the highest when the borderline was 21 mm. The *x* axis represents the borderline value (mm), whereas the *y* axis represents the difference between linear approximation angles of approximation lines.

Therefore, similar to the histogram analysis, geometric analysis with linear approximation also indicated that *I*~3~ = 21 mm is the threshold size of medical tablets and capsules that patients feel are too large to ingest.

Discussion {#S0004}
==========

In this study, the authors aimed to determine the upper threshold size of medical tablets and capsules for patients using histograms and geometric analyses with 709 reports collected by MSs of a medical wholesaler. The two analyses both suggested that *I*~3~ = 21 mm is the threshold size of medical tablets and capsules that patients feel are too large to ingest.

When designing or improving a drug in the form of a tablet/capsule, it is essential to take certain measures (eg, scoring, splitting into smaller doses, or redesigning as an orally disintegrating formulation) if *I*~3~ of the medical tablet/capsule is ≥21 mm. However, care should be taken and suitable options should be considered depending on the characteristics of the drug and the situation. Studies have shown that splitting a drug into smaller doses, thereby increasing the number, can be a burden on some patients.[@CIT0019] In addition, orally disintegrating tablets cannot always be helpful; they were already included in the problem reports in this study; they have stability problems, especially due to their hygroscopic nature, making it difficult to help patients using one-dose packages.[@CIT0020],[@CIT0021]

As for *I~1~* (length), two peaks were observed in the histogram. Further investigation revealed that the first peak mainly included round medical tablets, while the second peak mainly consisted of oval medical tablets and capsules. Accordingly, histogram analysis showed that a diameter of 8 mm can also be the threshold size, as long as round medical tablets are concerned. This is consistent with some previous reports stating that a diameter of 7.0--7.9 mm is appropriate for round medical tablets.[@CIT0007],[@CIT0013]

This study has some novelty and strengths. First, it used MSs of a medical wholesaler for postmarketing surveillance for collecting information and generated knowledge from it. In Japan, postmarketing surveillance is mainly operated by MRs of pharmaceutical companies. However, the MSs of medical wholesalers are considered as better information collectors than MRs because they deal with a wider range of medicines and visit medical institutions more frequently.

Second, a wide range of information was collected. Its great coverage and efficiency over community pharmacies enabled this study to consider a wide range of patient problems and requests, and to generalize the collected information to obtain universal knowledge.

The study also had some limitations. First, the information was collected only in Japan, especially Tokyo region. A previous study conducted in the United Kingdom suggested a threshold diameter of 13 mm for round tablets,[@CIT0011] implying regional differences. Therefore, similar studies in different regions of Japan and/or other countries could lead to differing and interesting conclusions. Incidentally, in October 2017, the PEM-MS system covered the entire Japan and is expected to collect and stock reports from regions other than Tokyo as well.

Second, this study did not consider the accurate volumes of drugs because exact data from pharmaceutical companies were not acquired or actual drugs were not assessed; however, the volume is relatively easy to check in the design process and worth considering.

Third, the PEM-MS system does not target detailed private information of patients; thus, we could not adjust the data based on the background data. Therefore, factors such as diseases or swallowing capabilities may influence the results of this study.

Finally, as mentioned before, the PEM-MS system was unable to collect large number of reports on medical tablet/capsules that are too small; therefore, this study did not reveal the threshold size of medical tablets/capsules that patients feel are too small. In the future, the continuously operating the PEM-MS system will accumulate more reports on medical tablets/capsules that are too small. This will also help to assess the threshold size of such tablet/capsules, enabling the determination of both the upper and lower threshold size of medical tablets/capsules and further adding value to the knowledge gained from this study.

This study is a completely new endeavor aiming to generate pharmaceutical knowledge from information collected by MSs of a medical wholesaler. As the objectives were mostly achieved, this study was successful and contributed to the activities of medical wholesalers and their MSs. Although postmarketing surveillance by MSs has not sufficiently permeated medical institutions, which is critical,[@CIT0022] the accumulation of similar reports and collaboration between MSs and other medical workers will surely accelerate medical wholesalers' participation in postmarketing surveillance and realize a more sophisticated global pharmaceutical industry and more effective drug evolution and fostering.

Conclusion {#S0005}
==========

*I*~3~ is a suitable index of medical tablet/capsule size, and *I*~3~ = 21 mm is the threshold size of medical tablet/capsules that patients feel are too large to ingest. In addition, for round tablets, a diameter of 8 mm is the threshold size. Medical tablets/capsules with *I*~3~ ≥ 21 mm are too large for patients to ingest. This study succeeded in obtaining useful pharmaceutical knowledge for drug formulation design and development from the postmarketing information collected by MSs of a medical wholesaler. Thus, postmarketing surveillance by MSs would continue to generate increasingly interesting and useful pharmaceutical knowledge.
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